These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 17666986)

  • 1. Ocular toxicities of epidermal growth factor receptor inhibitors and their management.
    Basti S
    Cancer Nurs; 2007; 30(4 Suppl 1):S10-6. PubMed ID: 17666986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature.
    Zhang G; Basti S; Jampol LM
    Cornea; 2007 Aug; 26(7):858-60. PubMed ID: 17667622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy.
    Tejwani A; Wu S; Jia Y; Agulnik M; Millender L; Lacouture ME
    Cancer; 2009 Mar; 115(6):1286-99. PubMed ID: 19170238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review.
    Borkar DS; Lacouture ME; Basti S
    Support Care Cancer; 2013 Apr; 21(4):1167-74. PubMed ID: 23151647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
    Modjtahedi H; Essapen S
    Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor as a target in cancer therapy.
    Kim ES
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S87-95. PubMed ID: 19795581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors.
    Galimont-Collen AF; Vos LE; Lavrijsen AP; Ouwerkerk J; Gelderblom H
    Eur J Cancer; 2007 Mar; 43(5):845-51. PubMed ID: 17289377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.
    Boone SL; Rademaker A; Liu D; Pfeiffer C; Mauro DJ; Lacouture ME
    Oncology; 2007; 72(3-4):152-9. PubMed ID: 18160805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapies in colorectal carcinoma: addressing toxicities associated with EGFR inhibitors.
    Biedrzycki BA
    ONS Connect; 2007; 22(8 Suppl):33-4. PubMed ID: 17824555
    [No Abstract]   [Full Text] [Related]  

  • 10. Nail toxicity associated with epidermal growth factor receptor inhibitor therapy.
    Fox LP
    J Am Acad Dermatol; 2007 Mar; 56(3):460-5. PubMed ID: 17147969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical approaches to minimize rash associated with EGFR inhibitors.
    Oishi K
    Oncol Nurs Forum; 2008 Jan; 35(1):103-11. PubMed ID: 18192159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular side effects of chemotherapy: nursing management.
    Cloutier AO
    Oncol Nurs Forum; 1992 Sep; 19(8):1251-9. PubMed ID: 1408967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer.
    Lacouture ME
    Cancer Nurs; 2007; 30(4 Suppl 1):S17-26. PubMed ID: 17666987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trichomegaly and other external eye side effects associated with epidermal growth factor.
    Fraunfelder FT; Fraunfelder FW
    Cutan Ocul Toxicol; 2012 Sep; 31(3):195-7. PubMed ID: 22122121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics.
    Hammond-Thelin LA
    Dermatol Clin; 2008 Jan; 26(1):121-59, ix. PubMed ID: 18023775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors.
    Balagula Y; Garbe C; Myskowski PL; Hauschild A; Rapoport BL; Boers-Doets CB; Lacouture ME
    Int J Dermatol; 2011 Feb; 50(2):129-46. PubMed ID: 21244375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conjunctival impression cytology, ocular surface, and tear-film changes in patients treated with systemic isotretinoin.
    Karalezli A; Borazan M; Altinors DD; Dursun R; Kiyici H; Akova YA
    Cornea; 2009 Jan; 28(1):46-50. PubMed ID: 19092405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.
    Tan EH; Chan A
    Ann Pharmacother; 2009 Oct; 43(10):1658-66. PubMed ID: 19755624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychosocial impact of cutaneous toxicities associated with epidermal growth factor receptor-inhibitor treatment.
    White KJ; Roydhouse JK; Scott K
    Clin J Oncol Nurs; 2011 Feb; 15(1):88-96. PubMed ID: 21278044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contact lenses and associated anterior segment disorders: dry eye disease, blepharitis, and allergy.
    Lemp MA; Bielory L
    Immunol Allergy Clin North Am; 2008 Feb; 28(1):105-17, vi-vii. PubMed ID: 18282548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.